Skip to content

Gomdori Medical

Evidence-Based Medical Education by gomdori, MD

MENU
  • Home
  • Gastroenterology
  • Procedures
  • Critical Care
  • More Specialties
    • Cardiovascular Medicine
    • Respiratory Medicine
    • Nephrology & Renal Care
    • Hematology
    • Oncology
    • Endocrinology
    • Allergy & Immunology
    • Infectious Diseases
    • Rheumatology
  • Tools
  • About gomdori Medical
  • Conference News
  • Clinical Library
Home » Upper GI Bleed Admission Order Set: A Comprehensive Clinical Protocol

Upper GI Bleed Admission Order Set: A Comprehensive Clinical Protocol

Posted on April 10, 2026October 30, 2026 by Gomdori
gomdori Medical · Clinical Order Set
Upper GI Bleed Admission Order Set: A Comprehensive Clinical Protocol
💊 Order Set gomdorimedical.com
Home › Order Sets › Upper GI Bleed Admission Order Set
gomdori Medical
Clinical Order Set

Upper GI Bleed Admission Order Set: A Comprehensive Clinical Protocol

📅 April 10, 2026 ✍️ gomdori ⏱ 18 min read ICU / Step-Down / Ward
Referenced Clinical Guidelines
ACG
American College of Gastroenterology
Clinical guidelines in gastroenterology
AGA
American Gastroenterological Association
Clinical practice guidance in gastroenterology
AASLD
American Association for the Study of Liver Diseases
Practice guidelines in hepatology
📋 Protocol at a Glance

This order set provides a structured admission protocol for acute upper gastrointestinal bleeding (UGIB), encompassing hematemesis, coffee-ground emesis, melena, and hematochezia with suspected upper GI source. The protocol addresses hemodynamic resuscitation with crystalloids and restrictive transfusion targets, high-dose intravenous proton pump inhibitor therapy, variceal-specific interventions including octreotide and antibiotic prophylaxis, and timely gastroenterology consultation for endoscopic evaluation. Admission criteria include any patient presenting with overt GI bleeding and hemodynamic compromise, significant hemoglobin drop, or high-risk Glasgow-Blatchford Score. The primary therapeutic goals are to achieve hemodynamic stability with MAP ≥65 mmHg, maintain hemoglobin between 7 and 9 g/dL via restrictive transfusion, correct coagulopathy, and facilitate endoscopy within 24 hours of presentation. This protocol is applicable across emergency department, intensive care unit, and step-down ward settings depending on severity stratification.

2–10%
In-Hospital Mortality
<24h
Endoscopy Time Target
7 g/dL
Transfusion Threshold
15–20%
Rebleeding Rate
Contents
  1. Assessment & Monitoring
    • GBS & Rockall Risk Scoring
  2. Laboratory Orders
  3. Medications
    • PPI Therapy & Variceal Meds
    • Anticoagulant Reversal
  4. IV Fluids & Infusions
  5. Conditional Orders
  6. Step-Down & Discharge
  7. Quick Reference
  8. Protocol Experience
    • Bedside lessons for upper GI bleed admissions
  9. FAQ
1

Assessment & Monitoring

Acute upper gastrointestinal bleeding demands rapid hemodynamic assessment, early risk stratification, and continuous monitoring to detect clinical deterioration. The initial evaluation should focus on confirming the bleeding source as upper GI through history and physical examination, establishing large-bore intravenous access with two 16-gauge or larger peripheral IV lines, and initiating volume resuscitation before any diagnostic procedures. All patients require formal risk scoring using the Glasgow-Blatchford Score at presentation to determine the need for intervention, and the complete Rockall Score after endoscopy to predict rebleeding and mortality risk. Continuous telemetry monitoring is mandatory for patients with hemodynamic instability or active hemorrhage. Nasogastric tube placement may be considered for diagnostic purposes when the source of bleeding is uncertain, though it is not required in all cases and does not improve clinical outcomes when the diagnosis is clear.

🔴 Admission Criteria
Hematemesis (bright red blood or coffee-ground emesis) • Melena or hematochezia with suspected upper GI source • Systolic blood pressure <90 mmHg or orthostatic hypotension (drop ≥20 mmHg on standing) • Heart rate >120 bpm • Hemoglobin drop >2 g/dL from baseline • Glasgow-Blatchford Score ≥1 (any score above 0 warrants inpatient evaluation) • Active anticoagulant or antiplatelet therapy with GI bleed • Suspected variceal hemorrhage or known cirrhosis with GI bleeding • Syncope or altered mental status with evidence of GI hemorrhage
Vital Signs
q1h × 6h, then q2h × 18h, then q4h when stable
Alert: SBP <90, HR >120, MAP <65
Hemoglobin / Hematocrit
q6h × 24h, then q8h × 48h, then q12h
Alert: Hgb <7 g/dL or drop >2 g/dL in 6h
Intake & Output
Strict I&O with hourly urine output monitoring
Alert: UOP <0.5 mL/kg/h × 2h
Stool Color & Frequency
Document every bowel movement (color, volume, consistency)
Alert: Bright red blood per rectum or recurrent melena
NGT Output (if placed)
q2h aspiration if NGT placed for lavage
Alert: Persistent bright red aspirate >200 mL
Mental Status & Neuro Checks
q2h × 12h, then q4h; GCS assessment
Alert: Confusion, agitation, GCS decline ≥2 points

Risk Stratification: Glasgow-Blatchford & Rockall Scores

Glasgow-Blatchford Score (GBS) — Pre-Endoscopy Risk Assessment
ParameterValueScoreClinical Implication
BUN (mg/dL)<18.20Low risk for intervention
BUN (mg/dL)18.2–22.32Moderate risk
BUN (mg/dL)22.4–27.93Moderate-high risk
BUN (mg/dL)28.0–69.94High risk
BUN (mg/dL)≥706Very high risk
Hemoglobin (men, g/dL)≥130Normal
Hemoglobin (men, g/dL)12.0–12.91Mild anemia
Hemoglobin (men, g/dL)10.0–11.93Moderate anemia
Hemoglobin (men, g/dL)<106Severe anemia
SBP (mmHg)≥1100Hemodynamically stable
SBP (mmHg)100–1091Borderline hypotension
SBP (mmHg)90–992Hypotension
SBP (mmHg)<903Shock
Heart Rate≥100 bpm1Tachycardia
MelenaPresent1Active lower source or UGIB
SyncopePresent2Hemodynamic compromise
Hepatic DiseasePresent2Portal hypertension risk
Heart FailurePresent2Limited resuscitation reserve
💡 GBS Interpretation
GBS = 0: Very low risk; consider outpatient management with urgent outpatient endoscopy. GBS 1–5: Low-intermediate risk; inpatient observation, endoscopy within 24 hours. GBS 6–11: Moderate-high risk; ICU or step-down admission, endoscopy within 12–24 hours. GBS ≥12: High risk; ICU admission, very early endoscopy within 12 hours, blood bank alert. Grade A
2

Laboratory Orders

Initial laboratory evaluation in acute UGIB serves three critical purposes: quantifying the severity of blood loss, identifying coagulopathy requiring correction, and establishing baseline values for serial trending. All STAT labs should be drawn immediately upon presentation, ideally before initiation of fluid resuscitation to obtain an accurate baseline hemoglobin. A type and screen is essential for all patients, and crossmatch of packed red blood cells should be ordered for any patient with hemodynamic instability or hemoglobin below 9 g/dL. Serial hemoglobin monitoring every 6 to 8 hours during the first 24 hours is critical because initial hemoglobin may not reflect the true degree of blood loss due to hemoconcentration from dehydration.

STAT Admission Labs STAT
CBC with differential, CMP (BUN, creatinine, electrolytes, glucose), PT/INR/aPTT, fibrinogen, type & screen, lactate, reticulocyte count
Blood Bank Orders STAT
Type & crossmatch 2–4 units pRBC (increase to 6 units if GBS ≥12 or active hemodynamic instability), request O-negative uncrossmatched blood if massive hemorrhage protocol activated
Additional Studies Once
Hepatic function panel (AST, ALT, albumin, total bilirubin), lipase, ammonia level (if cirrhosis suspected), serum iron & ferritin, pregnancy test (women of childbearing age)
Serial Trending Labs q6–8h
Hemoglobin & hematocrit q6h × 24h then q8h × 48h, BMP q12h (monitor potassium and creatinine during resuscitation), lactate q6h until normalized (<2 mmol/L), INR q12h if on anticoagulant reversal

Laboratory Panel Discipline: Trends Beyond Admission

Beyond the standard CBC, CMP, lipase, lactate, and coagulation profile ordered at admission, the highest-yield laboratory discipline in upper gastrointestinal bleeding is serial hemoglobin trending at hours 4, 8, 12, and 24 from admission. A falling hemoglobin trajectory despite ongoing transfusion or stable trajectory above 8 g/dL with active clinical bleeding signals ongoing hemorrhage requiring intervention escalation. Type and crossmatch with at least 2 units cross-matched at admission, with additional cross-matched units available for any patient with hemodynamic instability or active visible bleeding. BUN-to-creatinine ratio above 30 supports upper GI source over lower GI in the patient with melena where source localization is unclear. Liver enzymes plus albumin plus INR establish hepatic synthetic function baseline — critical when considering variceal etiology and procedural anticoagulation reversal. Procalcitonin is reserved for cases with concurrent sepsis features. Repeat coagulation profile every 6 hours during active hemorrhage to monitor dilutional coagulopathy from massive transfusion and guide fresh frozen plasma or prothrombin complex concentrate replacement. Cardiac troponin in the elderly patient with significant blood loss captures demand ischemia that may otherwise be silent during acute resuscitation and influences transfusion threshold decisions.

3

Medications

Primary Acid Suppression Therapy

Pantoprazole (Protonix) — High-Dose IV PPI STAT

Dose: Pantoprazole (Protonix) 80 mg IV bolus, then 8 mg/hr continuous infusion × 72h

Indication: High-risk ulcer stigmata after endoscopic hemostasis (active bleeding, visible vessel, adherent clot). May initiate empirically pre-endoscopy if endoscopy delayed >12 hours. Grade A

Renal adjust: No dose adjustment required for renal impairment. Hepatic impairment (Child-Pugh C): consider reduced dose to 40 mg bolus then 4 mg/hr.

Monitor: Serum magnesium if infusion >72h, hepatic function, signs of C. difficile infection with prolonged use.

⚠️ High-alert medication — Continuous infusion requires dedicated IV line. Y-site incompatible with midazolam and octreotide. Verify rate at 8 mg/hr (100 mL/hr of standard 8 mg/100 mL concentration). Do not bolus through same line as blood products.
12
NNT
High-dose PPI to prevent rebleeding after endoscopy
77
NNH
C. difficile with prolonged IV PPI >72h

Variceal Bleed Protocol

Octreotide (Sandostatin) — Variceal Hemorrhage STAT

Dose: Octreotide (Sandostatin) 50 mcg IV bolus, then 50 mcg/hr continuous infusion × 3–5 days

Indication: Suspected or confirmed variceal hemorrhage. Initiate immediately when variceal source is suspected (known cirrhosis, portal hypertension, or spider angiomata with GI bleed). Grade A

Renal adjust: No specific renal dose adjustment. Use with caution in dialysis patients due to reduced clearance; consider 25 mcg/hr.

Monitor: Blood glucose q6h (risk of hypoglycemia and hyperglycemia), cardiac rhythm (QTc prolongation risk), abdominal pain or diarrhea, thyroid function with prolonged use >5 days.

Ceftriaxone (Rocephin) — Antibiotic Prophylaxis STAT

Dose: Ceftriaxone (Rocephin) 1 g IV q24h × 7 days

Indication: Antibiotic prophylaxis for all cirrhotic patients with GI bleeding. Reduces bacterial infections, spontaneous bacterial peritonitis, rebleeding, and mortality. Grade A

Renal adjust: No dose adjustment needed for renal impairment. Avoid concurrent calcium-containing IV solutions (risk of ceftriaxone-calcium precipitate).

Monitor: Daily CBC, hepatic panel, signs of biliary sludge with prolonged use, C. difficile-associated diarrhea.

Pre-Endoscopy Prokinetic

Erythromycin (Erythrocin) — Prokinetic Agent Once

Dose: Erythromycin (Erythrocin) 250 mg IV single dose 30–60 min before endoscopy

Indication: Pre-endoscopy gastric emptying to improve endoscopic visualization. Most beneficial when large blood clot burden is expected (active hematemesis, large-volume coffee-ground emesis). Grade B

Renal adjust: No renal adjustment required. Hepatic impairment: use with caution (hepatotoxicity risk); avoid in severe hepatic failure.

Monitor: QTc interval (obtain baseline ECG), infusion site for phlebitis, concurrent QTc-prolonging medications. Infuse over 20–30 minutes to reduce GI side effects.

⚠️ Relative Contraindication — Erythromycin
Known QTc prolongation >500 ms or concurrent use of class IA/III antiarrhythmics. Severe hepatic impairment (Child-Pugh C). Concurrent use of CYP3A4 substrates with narrow therapeutic index (ergotamine, simvastatin >20 mg). Alternative: Metoclopramide (Reglan) 10 mg IV single dose if erythromycin contraindicated.

Supportive & PRN Medications

Ondansetron (Zofran) — Antiemetic PRN

Dose: Ondansetron (Zofran) 4 mg IV q6h PRN nausea/vomiting

Indication: Nausea or vomiting not attributable to active hemorrhage. Particularly useful post-endoscopy or during octreotide infusion.

Max: 16 mg/day. Reduce to 8 mg/day max in severe hepatic impairment (Child-Pugh C).

Monitor: QTc interval (additive risk with erythromycin or octreotide), constipation, headache.

Sucralfate (Carafate) — Mucosal Protectant Routine

Dose: Sucralfate (Carafate) 1 g PO QID (1h before meals and at bedtime)

Indication: Mucosal protection after endoscopic hemostasis of gastric or duodenal ulcers. Initiate once patient tolerates oral intake. Grade C

Renal adjust: Use with caution in CrCl <30 mL/min (aluminum accumulation risk). Avoid in dialysis patients.

Monitor: Constipation, drug interactions (separate from PPI, fluoroquinolones, and levothyroxine by ≥2 hours). Bezoar risk with impaired gastric motility.

Anticoagulant Reversal Orders

Anticoagulant Reversal — Warfarin / DOAC STAT

Warfarin reversal (INR >2.5 with active bleeding):

Vitamin K (phytonadione) 10 mg IV slow infusion over 30 min PLUS 4-factor PCC (Kcentra) 25–50 units/kg IV (dose based on INR: INR 2–4 = 25 units/kg; INR 4–6 = 35 units/kg; INR >6 = 50 units/kg)

Dabigatran reversal: Idarucizumab (Praxbind) 5 g IV as two 2.5 g boluses no more than 15 min apart

Rivaroxaban/Apixaban reversal: Andexanet alfa (Andexxa) low-dose: 400 mg IV bolus at 30 mg/min, then 4 mg/min × 120 min; or high-dose per last dose timing

Monitor: INR q2h after PCC until <1.5, repeat INR at 6h and 24h. For DOAC reversal, anti-Xa levels if available. Watch for thrombotic complications post-reversal.

⚠️ High-alert medication — 4-factor PCC carries thrombotic risk (DVT, PE, stroke, MI). Use lowest effective dose. Hematology consult recommended for complex anticoagulation reversal. Do not use FFP as first-line reversal for warfarin in acute hemorrhage.

Medications to AVOID

⛔ Absolute Contraindication
Tranexamic acid: NOT recommended for GI bleeding. The HALT-IT trial demonstrated no reduction in mortality, rebleeding, or need for surgery, and showed an increased risk of venous thromboembolic events including DVT and PE. Do not order tranexamic acid for any UGIB indication. Grade A
⛔ Absolute Contraindication
NSAIDs (ibuprofen, naproxen, ketorolac): Discontinue all NSAIDs immediately. NSAIDs inhibit cyclooxygenase-mediated prostaglandin synthesis, impairing mucosal defense and promoting ulcer formation. Do not restart until ulcer healing is confirmed by follow-up endoscopy and only with PPI co-therapy. For analgesia, use acetaminophen 1 g PO/IV q6h (max 3 g/day in liver disease).

Admission order set

Upper GI bleeding: key orders around endoscopy

  1. 1

    1. Transfusion when hemodynamically stable

    • No cardiovascular disease: transfuse at Hgb <7 g/dL; target Hgb 7–9 g/dL
  2. 2

    2. Variceal bleeding or cirrhosis

    • Suspected variceal: octreotide 50 mcg IV bolus, then 50 mcg/hr for 3–5 days
    • Cirrhosis with GI bleeding: ceftriaxone 1 g IV q24h
    • Suspected variceal: endoscopy within 12 hours; avoid excessive crystalloid
  3. 3

    3. Patient on warfarin

    • Hold all anticoagulation; reversal should not delay endoscopy
  4. 4

    4. Before endoscopy

    • Active bleeding: baseline ECG, then erythromycin 250 mg IV once, 30⁠–⁠60 min before endoscopy, over 20⁠–⁠30 min

    Caution: Not with macrolide allergy, QT prolongation or ventricular arrhythmia, low K or Mg, or interacting drugs (e.g., domperidone, simvastatin, ergotamine, class IA/III antiarrhythmics).

  5. 5

    5. Peptic ulcer at endoscopy

    • Forrest Ia, Ib (spurting, oozing) or IIa (nonbleeding visible vessel): endoscopic hemostasis
    • Actively bleeding ulcer: epinephrine injection plus contact thermal or mechanical therapy

    Caution: Do not use epinephrine injection as monotherapy.

  6. 6

    6. After endoscopy for high-risk ulcer

    • Active bleeding, visible vessel or adherent clot: pantoprazole 80 mg IV bolus, then 8 mg/hr × 72 h

Do not order tranexamic acid for any upper GI bleeding indication; stop non‑aspirin NSAIDs.

Steps 1–3 apply from presentation, by patient group; other doses and exceptions are in the text. Sources: This article; ESGE peptic ulcer bleeding guideline, update 2026; Erythromycin lactobionate SmPC (emc)
4

IV Fluids & Infusions

Hemodynamic resuscitation in acute UGIB should follow a goal-directed approach targeting MAP ≥65 mmHg, heart rate <100 bpm, and urine output ≥0.5 mL/kg/h. Crystalloid resuscitation with lactated Ringer solution is preferred over normal saline due to lower risk of hyperchloremic metabolic acidosis, though normal saline is acceptable when LR is unavailable. Avoid excessive fluid resuscitation in suspected variceal hemorrhage, as aggressive volume expansion can worsen portal pressure and increase rebleeding risk. The restrictive transfusion strategy targeting hemoglobin 7 g/dL has demonstrated superior outcomes compared to liberal transfusion in hemodynamically stable patients, with reductions in rebleeding, mortality, and adverse events. Massive transfusion protocol should be activated when estimated blood loss exceeds 1500 mL, ongoing hemorrhage requires more than 4 units pRBC in 1 hour, or hemodynamic instability persists despite 2 liters of crystalloid.

IV MIX Crystalloid Resuscitation & pRBC Transfusion Protocol
  • Lactated Ringer (LR) 500 mL IV bolus over 15–30 min; repeat up to 2 L total as needed to achieve MAP ≥65 mmHg
  • If Hgb <7 g/dL: Transfuse 1 unit pRBC over 90–120 min (or 15–30 min in acute hemorrhagic shock); target Hgb 7–9 g/dL
  • If massive hemorrhage protocol activated: pRBC:FFP:platelets in 1:1:1 ratio; notify blood bank for uncrossmatched O-negative release
  • For variceal bleed: Limit crystalloid to 1 L; prioritize blood products over crystalloid to avoid portal pressure elevation
Target: MAP ≥65 mmHg, Hgb 7–9 g/dL, UOP ≥0.5 mL/kg/h
IV MIX Pantoprazole Continuous Infusion
  • Reconstitute pantoprazole 80 mg vial with 10 mL NS; further dilute in 100 mL NS bag (concentration: 0.8 mg/mL)
  • Administer 80 mg IV bolus over 15 minutes via dedicated peripheral or central line
  • Immediately follow bolus with continuous infusion at 8 mg/hr (10 mL/hr of 0.8 mg/mL solution); prepare new bag q10h
  • Protect from light. Compatible with NS and D5W only. Do NOT mix with other IV medications or blood products.
Rate: Pantoprazole 8 mg/hr continuous IV infusion × 72h (80 mg in 100 mL NS at 10 mL/hr)
IV MIX Octreotide Continuous Infusion
  • Add Octreotide 250 mcg (1 mL of 500 mcg/mL vial) to 250 mL NS (final concentration: 1 mcg/mL)
  • Administer 50 mcg IV bolus over 3–5 minutes (50 mL of 1 mcg/mL solution or from stock vial)
  • Start continuous infusion at 50 mcg/hr (50 mL/hr of 1 mcg/mL concentration) for 3–5 days
Rate: Octreotide 50 mcg/hr continuous IV infusion (250 mcg in 250 mL NS at 50 mL/hr)

Admission timeline

Acute upper GI bleeding

  1. At presentation

    IV access, labs, first drugs

    • Two 16-gauge or larger IVs; STAT labs, type and screen; Glasgow-Blatchford Score; GI consult ≤2 h
    • Variceal suspicion (incl. known cirrhosis): octreotide, ceftriaxone
    • Hold anticoagulants; do not delay endoscopy for reversal
  2. Before any diagnostic procedure

    Hemodynamic resuscitation

    • Unstable: LR 500 mL IV boluses to MAP ≥65 mmHg, up to 2 L (≤1 L if variceal suspicion)
    • Still unstable and bleeding: ICU; massive transfusion protocol (no FFP if variceal suspicion)
    • Stable: transfuse at Hgb <7 g/dL; cardiovascular disease: ≤8 g/dL
  3. 30–60 min before endoscopy

    Erythromycin 250 mg IV

    • Active bleeding: single dose over 20–⁠30 min, after a baseline ECG

    Caution: Do not give with QT prolongation, prior ventricular arrhythmia, macrolide allergy, low K or Mg, or interacting drugs.

  4. Within 24 h of presentation

    Endoscopy

    • Variceal suspicion: ≤12 h
    • Unstable despite resuscitation: as soon as safely possible
  5. After endoscopy

    PPI for ulcers, rebleeding plan

    • Ulcer with endoscopic hemostasis or adherent clot: pantoprazole 80 mg IV, then 8 mg/h for 72 h
    • Nonvariceal rebleeding: repeat endoscopy; if it fails, consider embolization, then surgery
  6. At discharge

    Criteria and plan

    • Hgb ≥7 g/dL, varying <0.5 g/dL on two consecutive checks ≥12 h apart; cardiovascular disease: transfuse at ≤8 g/dL
    • Oral diet tolerated ≥24 h; ulcer bleeding: on oral PPI ≥12 h
    • Avoid NSAIDs except secondary-prevention aspirin; antithrombotic plan; treat H. pylori if positive
Presentation to discharge. Sources: This article; ESGE 2021, 2022, 2026; Baveno VII, 2022; NICE CG141; Erythromycin SmPC, 2024
5

Conditional Orders

Conditional orders define the branching logic for managing clinical deterioration, unexpected laboratory findings, and escalation scenarios in acute UGIB. Each condition below represents a measurable clinical trigger paired with a specific intervention including drug name, dose, and route. These orders should be entered in the electronic medical record as standing conditional orders so that nursing staff can execute them without delay while awaiting physician reassessment. Early activation of the massive transfusion protocol and timely GI consultation are the two most time-critical conditional actions in this order set.

Active hematemesis (bright red blood or large-volume coffee-ground emesis)
NPO status immediately. GI consult STAT for urgent endoscopy. Position patient in left lateral decubitus. Ensure airway protection; consider elective intubation if massive hematemesis with aspiration risk. Anesthesia consult for airway management if GCS <8.
SBP <90 mmHg or MAP <65 mmHg despite 1 L crystalloid bolus
Administer LR 500 mL IV bolus over 15 min. Activate massive transfusion protocol if ongoing hemorrhage. Start norepinephrine (Levophed) 0.05 mcg/kg/min IV if MAP remains <65 after 2 L crystalloid and 2 units pRBC. Transfer to ICU. Place central venous catheter and arterial line.
Hemoglobin <7 g/dL (or <8 g/dL with acute coronary syndrome)
Transfuse 1 unit pRBC; recheck Hgb 1 hour post-transfusion. Target Hgb 7–9 g/dL for most patients. For ACS patients, target Hgb ≥8 g/dL. If platelets <50,000/mcL with active bleeding, transfuse 1 unit apheresis platelets. If fibrinogen <150 mg/dL, administer cryoprecipitate 10 units.
INR >2.5 with active bleeding in patient on warfarin
Administer 4-factor PCC (Kcentra) 25–50 units/kg IV (dose per INR level) PLUS Vitamin K 10 mg IV over 30 min. Recheck INR in 30 minutes. Hold all anticoagulation. Hematology consult for anticoagulation restart timing after hemostasis achieved.
Suspected variceal hemorrhage (known cirrhosis, stigmata of liver disease, or portal hypertension)
Start octreotide (Sandostatin) 50 mcg IV bolus then 50 mcg/hr infusion. Start ceftriaxone (Rocephin) 1 g IV q24h. GI consult for endoscopy within 12 hours. Avoid excessive crystalloid resuscitation. Target restrictive Hgb 7 g/dL. Consider TIPS referral if band ligation fails to control hemorrhage.
Lactate >4 mmol/L or rising lactate despite resuscitation
Reassess volume status and bleeding source. Increase fluid resuscitation. Consider vasopressor support if MAP <65. Repeat lactate in 2 hours. If lactate continues to rise, escalate to ICU for invasive hemodynamic monitoring and consider emergent surgical or interventional radiology consultation.
Upper GI Bleed Conditional Order Decision Algorithm Decision tree showing three critical conditional branches for acute upper GI bleeding management: hemodynamic instability, suspected variceal source, and coagulopathy reversal. UGIB Conditional Order Algorithm Acute UGIB Presentation SBP <90 / MAP <65 LR 500 mL bolus x2 pRBC if Hgb <7 g/dL Vasopressor if refractory ICU Transfer Suspected Variceal Octreotide 50 mcg bolus + 50 mcg/hr infusion Ceftriaxone 1 g IV q24h EGD within 12h INR >2.5 / On DOAC 4-factor PCC 25-50 U/kg + Vitamin K 10 mg IV Recheck INR in 30 min Hematology Consult All Paths: GI Consult + Endoscopy ≤24h
🏥 When to Refer / Escalate
GI consult STAT: All patients with acute UGIB require GI consultation within 2 hours of presentation for endoscopy planning. Emergent endoscopy within 2 hours for hemodynamic instability despite resuscitation or massive ongoing hemorrhage.
ICU transfer: MAP <65 mmHg requiring vasopressor support, need for mechanical ventilation or airway protection, massive transfusion protocol activation (>4 units pRBC in 1 hour), or persistent hemodynamic instability after 2 L crystalloid and 2 units pRBC.
Interventional radiology consult: Rebleeding after two endoscopic hemostasis attempts, anatomically inaccessible bleeding source, or endoscopic failure to achieve hemostasis.
Surgery consult: Uncontrolled hemorrhage despite endoscopic and IR intervention, perforation complicating endoscopic therapy, or massive hemorrhage from gastric malignancy.
Hepatology / Transplant referral: Refractory variceal bleeding despite band ligation and pharmacotherapy; consider TIPS (transjugular intrahepatic portosystemic shunt) for salvage therapy.
❓ Areas of Uncertainty
  • Optimal timing of anticoagulation resumption after UGIB hemostasis in patients with mechanical heart valves or recent VTE
  • Role of pre-endoscopy PPI infusion versus bolus dosing in patients who undergo endoscopy within 6 hours of presentation
  • Benefit of erythromycin prokinetic when endoscopy is performed within 4 hours of last emesis episode
6

Step-Down & Discharge

Step-Down to Ward Criteria

  • Hemodynamically stable for ≥12 hours: SBP ≥100 mmHg, HR <100 bpm without vasopressor support
  • No evidence of rebleeding for ≥24 hours: stable Hgb (variation <1 g/dL over 12h), no recurrent hematemesis or melena
  • Afebrile (<38.0°C) with no signs of infection for ≥12 hours
  • Endoscopic hemostasis achieved with Forrest Ib or better classification on follow-up assessment
  • Off vasopressors and continuous PPI infusion transitioned to intermittent IV or oral PPI

Discharge Criteria

  • Hemoglobin stable (≥7 g/dL, variation <0.5 g/dL) on two consecutive checks ≥12 hours apart
  • Tolerating oral diet without nausea, vomiting, or recurrent GI symptoms for ≥24 hours
  • Successfully transitioned from IV to oral PPI for ≥12 hours
  • Anticoagulation plan documented: timing of restart, bridging strategy if needed, and outpatient monitoring plan
  • GI follow-up endoscopy scheduled within 6–8 weeks for ulcer healing assessment and H. pylori status
  • Patient education completed: alarm symptoms (recurrent hematemesis, melena, lightheadedness), medication adherence, NSAID avoidance, alcohol cessation counseling if applicable

Discharge Medications

Medications to continue at discharge
DrugDoseDurationFollow-up Labs
Pantoprazole (Protonix)Pantoprazole 40 mg PO BID8–12 weeksRepeat EGD at 8 weeks for ulcer healing; Mg level if >3 months
H. pylori eradication (if positive)PPI BID + Clarithromycin 500 mg BID + Amoxicillin 1000 mg BID × 14 days14 days (start after acute phase resolves)H. pylori stool antigen 4 weeks after completing treatment (off PPI ≥2 weeks)
Ferrous sulfateFerrous sulfate 325 mg PO daily (65 mg elemental iron)3–6 months or until ferritin >100CBC, iron studies, ferritin at 4 weeks and 3 months
Sucralfate (if post-ulcer)Sucralfate 1 g PO QID × 4–8 weeks4–8 weeksNone routinely; renal function if CKD
📋 Patient Summary

You were admitted for bleeding in your upper digestive tract. You received an intravenous medication called pantoprazole to reduce stomach acid and help your stomach heal. You may have also received blood transfusions and a procedure called an endoscopy to find and treat the bleeding source. At discharge, you will continue taking pantoprazole by mouth twice daily for 8 to 12 weeks. If a bacteria called H. pylori was found, you will also take antibiotics for 14 days. Take iron supplements daily to rebuild your blood counts. Avoid all NSAIDs (ibuprofen, naproxen, aspirin unless prescribed for your heart), limit alcohol, and return immediately if you vomit blood, notice dark or tarry stools, feel lightheaded, or pass out.

7

Quick Reference Card

📱 Bedside Quick Reference
First-Line PPI
Pantoprazole 80 mg IV bolus → 8 mg/hr × 72h
Transfusion Threshold
Hgb <7 g/dL (restrictive). Target 7–9 g/dL. Liberal (<9) only for ACS.
GI Consult Timing
Within 2h of presentation. EGD ≤24h (stable) or ≤12h (unstable / variceal).
NPO Rule
NPO until post-endoscopy assessment. Clear liquids if low-risk and EGD >12h away.
Variceal Protocol
Octreotide 50 mcg bolus → 50 mcg/hr + Ceftriaxone 1 g IV q24h × 7d
Avoid
NSAIDs, tranexamic acid, excessive crystalloid in variceal bleed, anticoagulants until hemostasis confirmed.
Rebleeding Rates at 30 Days (%) Horizontal bar chart: Rebleeding Rates at 30 Days (%) Rebleeding Rates at 30 Days (%) Peptic ulcer (post-endoscopic Tx) 15% Variceal (post-EVL) 25% Mallory-Weiss tear 5% Dieulafoy lesion 20% Cancer-related 40%
UGIB Outcomes by Etiology

Protocol Experience: Where the Order Set Slips and How Experienced Clinicians Adjust

(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)The endoscopist is asleep at home, the stomach is filling with clot, and the ward waits for morning, which makes upper gastrointestinal bleeding order sets the field where the most consistent practice gap they correct is the failure to administer pre-endoscopic erythromycin in any patient with active UGIB. The 30-60 minute window between admission decision-to-endoscope and the actual procedure is wasted in most order sets when erythromycin 250 mg IV could be improving endoscopic visualization meaningfully — a free, simple, evidence-aligned intervention that nonetheless gets routinely omitted.

Where Bundles Slip in Practice

Pre-endoscopic erythromycin 250 mg IV administered 30-60 minutes before endoscopy is the under-utilized intervention experienced practitioners add to every UGIB order set. The prokinetic effect clears stomach contents and active blood, improves mucosal visualization, reduces the need for second-look endoscopy, and is essentially free in cost and complications. Yet most order sets they encounter in referrals do not include it, and the endoscopist arrives at a stomach full of blood and clot that delays definitive treatment.

Re-Assessment Rhythm

Glasgow-Blatchford Score at admission triages outpatient candidate (GBS 0-1) from admission, vitals every hour for the first 8 hours then every 2 hours through hour 24, hemoglobin every 4 hours for the first 24 hours with type-and-screen renewal as needed. The trajectory of these markers — not single timepoint values — drives the escalation decisions. A patient whose hemoglobin is dropping despite transfusion is rebleeding, and IR consultation is initiated rather than another unit of blood.

Escalation Tripwire

Failed endoscopic hemostasis or rebleeding after initial endoscopic therapy triggers immediate interventional radiology consultation for selective transcatheter embolization, not surgical referral first. IR embolization has supplanted surgery as the first-line salvage after failed endoscopy in non-variceal UGIB, with lower morbidity, faster intervention, and equivalent or better outcomes in modern series. Surgery is reserved for patients in whom IR embolization is not anatomically feasible or has failed.

Variceal Doctrine

Variceal suspicion — established cirrhosis, known portal hypertension, prior variceal bleed, ascites, splenomegaly — triggers immediate ceftriaxone 1 g IV plus octreotide drip (50 mcg IV bolus + 50 mcg/hour infusion) even before endoscopic confirmation. The prophylactic antibiotic reduces bacterial peritonitis and mortality in cirrhotic UGIB; octreotide reduces splanchnic blood flow and aids hemostasis. Both can be initiated empirically and discontinued if non-variceal etiology is confirmed.

Illustrative Scenario

A man in his late sixties presented to the emergency department with 24 hours of intermittent melena, lightheadedness, and one episode of coffee-ground emesis. Vital signs showed blood pressure 92/56, heart rate 118, oxygen saturation 96% on room air. Hemoglobin was 7.2 g/dL on arrival, BUN 48 mg/dL (creatinine 1.0, ratio 48 suggesting upper GI source), INR 1.0, platelets 142. Glasgow-Blatchford Score was 11 (high risk admission). The treating clinicians initiated restrictive transfusion targeting hemoglobin 7-9 g/dL given absence of cardiac disease, IV pantoprazole 80 mg bolus followed by 8 mg/hour infusion, ondansetron for nausea, and crucially erythromycin 250 mg IV administered 45 minutes before the planned endoscopy. Upper endoscopy performed within 6 hours of admission revealed a 12 mm duodenal bulb ulcer with Forrest IIa visible vessel — high-risk stigmata. Combination endoscopic hemostasis was performed with epinephrine injection, hemoclip placement on the visible vessel, and adjacent bipolar coagulation. The PPI infusion was continued for 72 hours then transitioned to oral pantoprazole 40 mg twice daily. Helicobacter pylori testing was positive and eradication therapy initiated. He was discharged on hospital day 4 with no rebleeding and a planned 4-week follow-up for H. pylori eradication confirmation.

The takeaway the treating clinicians carry: pre-endoscopic erythromycin plus restrictive transfusion plus IV PPI bolus-then-drip plus appropriate endoscopic combination hemostasis plus H. pylori test-and-treat is the modern UGIB pathway. The single addition of erythromycin to a 30-60 minute window that previously sat idle has been the most consistent practice-shifting intervention in this disease.

Practice Protocol Adjustments to the Standard Order Set

  1. Erythromycin 250 mg IV 30-60 minutes before any planned endoscopy for active UGIB. Prokinetic effect clears stomach contents, improves mucosal visualization, reduces second-look endoscopy need. Free intervention that most order sets routinely omit.
  2. Restrictive transfusion targeting hemoglobin 7-9 g/dL (Hgb <7 trigger), with <8 g/dL threshold in active cardiac disease only. Liberal transfusion (Hgb <9) historical pattern is associated with increased rebleeding and mortality per Villanueva 2013 NEJM and replication studies.
  3. Variceal suspicion triggers immediate empiric ceftriaxone 1 g IV + octreotide drip (50 mcg bolus + 50 mcg/hour) before endoscopic confirmation. Prophylactic antibiotic reduces SBP and mortality in cirrhotic UGIB; octreotide reduces splanchnic blood flow. Both discontinued if non-variceal etiology confirmed.
  4. Failed endoscopic hemostasis: IR embolization first-line over surgery. Selective transcatheter embolization produces lower morbidity, faster intervention, and equivalent or better outcomes than surgical salvage in non-variceal UGIB. Surgery reserved for IR-infeasible or IR-failed cases.
GBS Scoring & Variceal vs Non-Variceal Triage Glasgow-Blatchford Score triage with variceal versus non-variceal etiology cascade and Forrest classification-driven endoscopic management GBS Scoring & Variceal vs Non-Variceal Triage Erythromycin pre-endoscopy + restrictive transfusion + IR salvage GBS Triage Cascade GBS 0-1: LOW-RISK Outpatient management eligible GBS 2-7: MODERATE Admission + EGD <24h GBS ≥8: HIGH-RISK ICU consideration + EGD <12h + Erythromycin 250mg IV pre-EGD 30-60 min before; improves view Restrictive Hgb <7 (Villanueva 2013) Target 7-9; <8 in active CAD only ★ Erythromycin under-utilized Variceal vs Non-Variceal Etiology VARICEAL SUSPICION (cirrhosis, PHT) Ceftriaxone 1g + octreotide drip empiric Variceal: EGD band ligation or sclerotherapy Plus TIPS consideration if refractory NON-VARICEAL: PPI 80mg + 8mg/hr drip Forrest Ia/Ib/IIa = combination hemostasis Forrest IIb/IIc/III = lower rebleed risk Single-modality or no intervention Failed EGD: IR embolization (NOT surgery) Lower morbidity; surgery only if IR fails ★ H. pylori test-and-treat post-stabilization
Left: Glasgow-Blatchford Score triage cascade with erythromycin pre-endoscopy and restrictive transfusion. Right: variceal versus non-variceal etiology pathway with IR embolization as first-line salvage.
8

Frequently Asked Questions

When should a restrictive versus liberal transfusion strategy be used in acute UGIB?
A restrictive transfusion strategy targeting hemoglobin 7 g/dL is recommended for hemodynamically stable patients without active coronary disease. Restrictive transfusion reduces mortality, rebleeding rates, and transfusion-related complications. Liberal transfusion targeting hemoglobin 9 g/dL should be reserved for patients with acute coronary syndrome, symptomatic anemia with hemodynamic instability, or massive hemorrhage with ongoing shock.
When should PPI continuous infusion versus intermittent dosing be initiated?
High-dose PPI continuous infusion with pantoprazole 80 mg IV bolus followed by 8 mg/hr for 72 hours is indicated after endoscopic hemostasis of high-risk ulcer stigmata including active bleeding, visible vessel, or adherent clot. Intermittent PPI dosing with pantoprazole 40 mg IV every 12 hours is appropriate for low-risk lesions such as clean-based ulcers or flat pigmented spots. Pre-endoscopy PPI infusion may be started empirically if endoscopy is expected to be delayed beyond 12 hours.
When should endoscopy be performed in acute upper GI bleeding?
Urgent endoscopy within 24 hours of presentation is recommended for all patients with acute UGIB after adequate hemodynamic resuscitation. Very early endoscopy within 12 hours is indicated for patients with hemodynamic instability, Glasgow-Blatchford Score of 12 or higher, or suspected variceal hemorrhage. Emergent endoscopy within 2 hours should be considered for patients with massive hemorrhage unresponsive to resuscitation or hematemesis with hemodynamic shock.
gomdori Medical — Upper GI Bleed Admission Order Set: A Comprehensive Clinical Protocol
Last updated: April 10, 2026 gomdorimedical.com
Related clinical topics
More in Gastroenterology
  • Lower GI Bleed Admission Order Set: Resuscitation, Colonoscopy Timing, and Management
  • Acute Pancreatitis Admission Order Set: Resuscitation, Pain Control, and Nutrition
  • Acute Cholangitis Admission Order Set: Antibiotics, Biliary Drainage, and Supportive Care
GUIDELINE REFERENCES

Primary guideline documents this article draws on. Links resolve via DOI to the publisher; access may require a subscription.

  • ACG 2021 Clinical Guideline: Upper GI and Ulcer Bleeding (American Journal of Gastroenterology · 2021)
Posted in GastroenterologyTagged blood transfusion protocol, endoscopy timing, gastrointestinal hemorrhage, GI bleed order set, Glasgow Blatchford score, hematemesis management, octreotide, PPI infusion, upper gi bleed, variceal bleeding

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

61 free tools

Endoscopy Findings Atlas · Explore endoscopic findings and diagnostic distinctions.

Health & clinical tools

Find personal records, research helpers and clinical references.

  • Personal Records & Visits11 tools
  • Measurements & Conversions3 tools
  • Research & Events11 tools
  • Clinical Scores & Tests16 tools
  • Medication & Treatment References14 tools
  • Screening & Procedures6 tools
Browse all 61 tools →

Clinical references are for qualified professionals. Check each tool’s scope and limitations.

Tools to try
  • AUDIT-C Alcohol Screening & Unit Calculator
  • Acute Pancreatitis Severity Calculator
  • Ascites SAAG & SBP Diagnostic Assistant
Support This Project
Help keep medical education free
Donate via PayPal

Recent Posts

  • PAPA Syndrome: PSTPIP1 Autoinflammatory Disease with Pyogenic Sterile Arthritis Pyoderma Gangrenosum and Cystic Acne
  • X-Linked Hypophosphatemia: PHEX FGF23 Renal Phosphate Wasting Hypophosphatemic Rickets and Burosumab Therapy
  • Rocky Mountain Spotted Fever (RMSF): Petechial Palm-Sole Rash, Empiric Doxycycline, and the Don’t-Wait-for-Confirmation Rule
  • Sideroblastic Anemia: Congenital ALAS2, Acquired MDS-RS, Reversible Toxic Causes, and Pyridoxine Therapy
  • Bartonella Endocarditis: B. henselae and B. quintana, Modified Duke Criteria, and Doxycycline-Gentamicin Therapy

Categories

  • Allergy & Clinical Immunology
  • Cardiovascular Medicine
  • Clinical Nutrition
  • Clinical Pharmacology
  • Critical Care Medicine
  • Dermatology
  • Emergency Medicine
  • Endocrinology & Metabolism
  • Gastroenterology
  • General Surgery
  • Geriatric Medicine
  • Hematology & Blood Disorders
  • Infectious Diseases
  • Medical Genetics
  • Nephrology & Renal Care
  • Neurology
  • Obstetrics & Gynecology
  • Occupational & Environmental Medicine
  • Oncology & Cancer Care
  • Ophthalmology
  • Order Sets
  • Orthopedics & Sports Medicine
  • Otolaryngology
  • Pain Medicine
  • Palliative Care
  • Pediatrics
  • Procedures
  • Psychiatry
  • Radiology
  • Respiratory Medicine
  • Rheumatology
  • Sleep Medicine
  • Urology
  • Vaccines & Preventive Medicine

Medical Disclaimer

This content is for educational and informational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider for clinical decision-making. The author assumes no liability for actions taken based on this content.

GM

Gomdori, MD

Gastroenterologist · Medical educator

A practising gastroenterologist in South Korea writing bedside-focused clinical education — guideline-derived, dose-precise, and aimed at the decision in front of you rather than the exam question.

Writes about

Gastroenterology & hepatologyEndoscopyGuideline appraisal

Editorial standard

  • Every figure is traced to a primary source and dated
  • Corrections are made on request — not quietly
  • Unverifiable data is omitted, never estimated
About the author Corrections

gomdori Medical

Evidence-based medical education by a practicing gastroenterologist in South Korea. Free clinical content for physicians, residents, and medical students.

Learn more →

Quick Links

  • Gastroenterology
  • Procedures
  • Critical Care
  • About
  • Medical Disclaimer

Contact

Corrections, topic requests, and feedback are always welcome.

gomdoridoctor@gmail.com

Support via PayPal

© 2026 gomdori Medical. All rights reserved.

Content is for educational purposes only and does not constitute medical advice. Full disclaimer

Built with clinical expertise & programmatic precision.

AboutToolsPrivacy PolicyTerms of UseEditorial PolicyDisclaimerContact
Free tools →

© 2026 Gomdori Medical. Educational content only — not professional advice. Figures are dated at the point of publication and change over time; verify against the original source before acting on them.

AboutToolsPrivacy PolicyTerms of UseDisclaimerContact
Free tools →

© 2026 Gomdori Medical. Educational content only — not professional advice. Figures are dated at the point of publication and change over time; verify against the original source before acting on them.

Copyright © 2026 Gomdori Medical – OnePress theme by FameThemes